Tandem motifs for construction of directed disulfide bond polycyclic peptide libraries and discovery of polycyclic peptide ligands

By designing the insertion of tandem motifs into the polypeptide chain, the construction of the quaternary cyclic peptide backbone is solved, and the problem of limited disulfide bond directed guidance motifs in the existing technology is expanded, and the structural and functional diversity of polycyclic peptides is achieved. The precise pairing and efficient oxidative folding of quaternary cyclic peptide molecules provide new targeted protein screening and therapeutic drug precursors.

CN119060128APending Publication Date: 2024-12-03XIAMEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411181871.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing disulfide bond directed guidance motif is limited, and it is difficult to directly use it to guide disulfide bond pairing of quaternary cyclic peptides and above cyclic peptides, which limits the structural diversity and functional diversity of polycyclic peptides.

Method used

Provide a set of tandem motifs, such as CPPCXC, CXCPPC, CPPCPXXC, CPXXCPPC, CXCPXXC, CPXXC, CXCXC, CPPCPPC and CPXXCPXXC. Through these motifs being inserted into the polypeptide chain, the construction of the quaternary cyclic peptide backbone and the precise regulation of polypeptide folding is achieved. , and phage display technology to construct a phage quaternary ring peptide library.

Benefits of technology

Expand the structural diversity of the multivariate cyclic peptide backbone, realize the precise pairing of four-pair disulfide bonds in the quadrimer cyclic peptide molecule, improve the oxidative folding efficiency of peptides, and provide new targeted protein screening tools and potential therapeutic drug precursors. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060128A_ABST
    Figure CN119060128A_ABST
Patent Text Reader

Abstract

The invention discloses a tandem motif used for constructing a directed disulfide bond polycyclic peptide library and finding a polycyclic peptide ligand, and relates to a cyclic peptide compound. The directional disulfide bond polycyclic peptide is a special polypeptide rich in disulfide bonds, a stable multi-element ring conformation is obtained through a disulfide bond directional guidance motif, and the directional disulfide bond polycyclic peptide can be combined with various targets in a high-affinity mode and can be used as a precursor for drug design. In order to expand the skeleton and structural diversity of the multi-element cyclic peptide, a group of disulfide bond directional guidance motifs with novel guidance disulfide bond folding properties, called series motifs, are designed. Two different tandem motifs are inserted into a polypeptide sequence, and peptide chain disulfide bond pairing and polypeptide folding can be effectively regulated and controlled. Different tandem motifs are inserted into a peptide chain, so that a DDMP skeleton of a four-membered ring topological structure is constructed. The skeleton does not need to borrow an oxidative folding template of natural disulfide bond-rich polypeptide, can be used for directly constructing a fully randomized polypeptide biological display library, and can be used for de novo design of multi-element cyclic peptide ligands and therapeutic drugs with new structures and new functions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to cyclic peptide compounds, in particular to constructing a directional disulfide bond multicyclic peptide library by serially connecting motifs and discovering multicyclic peptide ligands. Background Art

[0002] In recent years, cyclic peptides have attracted increasing attention as an attractive molecular form for disease diagnosis and treatment. Cyclic peptides constrain the peptide chain structure through covalent bonds, unlike proteins, which must rely on a large non-covalent interaction core to maintain a stable three-dimensional structure of the entire molecule. Cyclic peptides have a larger surface area to volume ratio than proteins. A particularly interesting example of cyclic peptides is the naturally occurring disulfide-rich peptides (DRPs), which mainly constrain the peptide chain structure through disulfide bonds. Most non-cysteine ​​residues in the DRPs sequence can be mutated without compromising the structural integrity, so the functional diversification of these DRPs can be achieved through molecular evolution to bind to various biological targets.

[0003] There are currently two main methods for developing disulfide-rich peptide molecules targeting different targets. One is to randomize part of the amino acid sequence as a cyclopeptide skeleton based on the natural DRP molecules existing in nature, and graft active peptide epitopes or construct a random peptide library to screen active sequences, giving the peptide new functions. However, the conservative disulfide bond structure of natural DRPs limits the structural diversity of DRPs - natural DRPs have only a few types of folding modes, including cystine knots, cystine-stabilized α / β folds, and three-finger toxin folds. In recent years, a new method has been developed to develop multi-functional cyclopeptides by motif-guided disulfide bond folding. This method does not require the use of natural cyclopeptide skeletons and non-natural amino acid insertions, but only requires a fixed disulfide bond-directed guiding motif, which can effectively improve the oxidative folding efficiency of polypeptides and expand the scope of randomized modification of polypeptide sequences. At the same time, this method can be effectively combined with various methods for the development of cyclopeptide ligands, including active epitope grafting, phage library construction and screening, yeast library construction and screening, mRNA display library construction and screening, etc. This type of motif-guided peptide is also called disulfide-directed multicyclic peptide (DDMPs). Disulfide-directed multicyclic peptides are a special class of disulfide-rich peptides that obtain stable multicyclic conformations through disulfide-directed guided motifs and can bind to a variety of targets with high affinity, and can be used as precursors for drug design. Based on disulfide-directed guided motifs, a large number of multicyclic peptide templates that tolerate sequence modifications can be designed to expand the limited folding structure templates of natural DRPs. At present, DDMPs molecules targeting a variety of biological target proteins have been reported, including CPPC-motif-guided CD28-targeting cyclic peptide drp8, MDM2-targeting drp1, Keap1-targeting drp6, CPXXC-motif-guided HER2-targeting cyclic peptide L-5, FGFR1-targeting cyclic peptide L-3, CXC-motif-guided MDM2-targeting cyclic peptide pb13, etc.

[0004] Currently, only three disulfide bond-directed guiding motifs have been discovered (CPPC, CXC, and CPXXC), and they can only be used to construct efficient oxidative folding bicyclic peptides and tricyclic peptide backbones. However, the theoretical number of isomers of polycyclic peptides greater than tricyclic is more than 100 (for example, the number of tetracyclic peptide isomers that can be theoretically produced after oxidation of the same polypeptide chain containing eight cysteine ​​residues is 105), and these motifs have limited guiding capabilities and are difficult to be directly used to guide the disulfide bond pairing of tetracyclic peptides and above. In order to explore polycyclic peptide molecules with higher affinity in sequence space, the present invention is committed to providing tandem motifs with diverse guiding capabilities, developing a cyclic peptide library with precise disulfide bond pairing, and thus screening functional polycyclic peptide molecules with better performance. Summary of the invention

[0005] The first purpose of the present invention is to address the problem that there are few disulfide bond-directed guiding motifs that can be used in the development process of existing DDMPs. In order to expand the diversity of polycyclic peptide skeletons and structures, a group of disulfide bond-directed guiding motifs with novel guided disulfide bond folding properties, called tandem motifs, are provided. The tandem motifs can be used to regulate the precise pairing of cysteine. Inserting two different tandem motifs into a polypeptide sequence can effectively regulate the disulfide bond pairing of peptide chains and polypeptide folding, thereby improving the efficiency of polypeptide oxidative folding.

[0006] The second object of the present invention is to provide the application of the group of tandem motifs for constructing a directional disulfide bond multi-cyclic peptide library and discovering multi-cyclic peptide ligands. By inserting different tandem motifs into the peptide chain, the DDMP skeleton of the four-membered ring topology is constructed. This skeleton does not need to borrow the oxidative folding template of the natural disulfide bond-rich polypeptide, and can be used to directly construct a fully randomized polypeptide biological display library to provide a tandem motif-guided three-membered cyclic peptide template. The precise pairing of four pairs of disulfide bonds in the four-membered cyclic peptide molecule is achieved. Combined with phage display technology, the four-membered cyclic peptide template is fused and expressed with the phage surface to construct a phage four-membered cyclic peptide library, which fully demonstrates that the tandem motif-guided multi-cyclic peptide method has good compatibility with the biological display technology.

[0007] The third object of the present invention is to provide the use of the polycyclic peptide ligands screened by the directional disulfide bond polycyclic peptide library as a research tool for chemical biology and a precursor molecule for the design of potential therapeutic drugs. Combined with NMR, the structure and disulfide bond pairing of two active DDMPs are determined, indicating that the method can effectively provide DDMP molecules with a completely new structure. Combined with fluorescent labeling, the affinity DDMP is used as a detection probe molecule for cell surface target proteins, indicating that the DDMP obtained by the present invention is a research tool for chemical biology and a precursor of potential therapeutic drugs.

[0008] To achieve the above object, the present invention provides the following technical solutions:

[0009] The present invention provides a group of tandem motifs, namely, CPPCXC, CXCPPC, CPPCPXXC, CPXXCPPC, CXCPXXC, CPXXCXC, CXCXC, CPPCPPC and CPXXCPXXC; wherein, C represents cysteine, P represents proline, and X represents any amino acid.

[0010] The group of tandem motifs is composed of disulfide bond-guided motifs CPPC, CPXXC and CXC as building blocks, and a cysteine ​​is shared between the motifs, so that the various motifs form a whole in function and structure. The shared cysteine ​​forms a disulfide bond between motifs in the polypeptide chain to stabilize the folded state of the peptide chain.

[0011] The tandem motifs CPPCXC, CXCPPC, CPPCPXXC, CPXXCPPC, CPPCPPC and CXCXC all have a strong tendency to pair in parallel and tolerate different numbers and positions of intra-motif amino acid mutations. These motifs can drive the polypeptide disulfide bond exchange reaction in the direction of parallel pairing of the tandem motifs.

[0012] The tandem motifs CPXXCXC, CXCPXXC and CPXXCPXXC have a certain antiparallel pairing tendency, which can drive the polypeptide to produce stable parallel pairing isomers and antiparallel pairing isomers, and the number of mutable amino acids in the motif is inconsistent. The disulfide bond pairing mode is achieved by selecting different tandem motif combinations.

[0013] The present invention provides a method for using the tandem motif to design a disulfide bond-guided multi-cyclic peptide library and discover multifunctional cyclic peptide ligands. The method comprises the following steps:

[0014] (1) Selecting tandem motifs to design a template for a directional disulfide bond polycyclic peptide backbone:

[0015] Template a: —aa m —A—aa n —

[0016] Template b:—aa m —A—aa n —B—aa o —

[0017] Template c: -aa m —A—aa n —C—aa o —C—aa p —A—aa q —

[0018] wherein A represents any one of the group of tandem motifs (CPPCXC, CXCPPC, CPPCPXXC, CXCPXXC, CXCPXXC, CPXXCXC, CXCXC, CPPCPPC and CPXXCPXXC), B represents a tandem motif, other disulfide bond-directed motifs (CPPC, CXC and CPXXC) or an additional cysteine, C represents an additional cysteine, aa represents any amino acid, and m, n, o, p and q all represent the number of any amino acids; in template b, the positions of A and B can be exchanged; in template c, the positions between A and C can be exchanged;

[0019] (2) Construction of a directional disulfide bond polycyclic peptide library

[0020] One of the three templates in step (1) is selected as the cyclopeptide backbone to construct a multi-component cyclopeptide library.

[0021] a. According to the tandem motif backbone in step (1), a DNA nucleic acid fragment containing the following sequence is synthesized, which forms a cyclic peptide structure containing a disulfide bond after translation:

[0022] TGCCCGCCGTGCNNKTGC, translated as CPPCXC;

[0023] TGCNNKTGCCCGCCGTGC, translated as CXCPPC;

[0024] TGCCCGCCGTGCCCGNNKNNKTGC, translated as CPPCPXXC;

[0025] TGCCCGNNKNNKTGCCCGCCGTGC, translated as CPXXCPPC;

[0026] TGCNNKTGCCCGNNKNNKTGC, translated as CXCPXXC;

[0027] TGCCCGNNKNNKTGCNNKTGC, translated as CPXXCXC;

[0028] TGCNNKTGCNNKTGC, translated as CXCXC;

[0029] TGCCCGCCGTGCCCGCCGTGC, translated as CPPCPPC;

[0030] TGCCCGNNKNNKTGCCCGNNKNNKTGC, translated as CPXXCPXXC;

[0031] Among them, by utilizing the codon degeneracy, TGC can be replaced by TGT, CCG can be replaced by CCC, CCA, CCT, and NNK refers to encoding random amino acid X by NNK degenerate codons, where N in NNK codons represents A, T, C and G, and K represents G and T; other random amino acid encoding methods (such as Trimer, IUBcode, etc.) can also be used to encode random amino acid X;

[0032] b. Construction of biological display library: The DNA nucleic acid fragments described in a are used for plasmid recombination to construct a biological display library; the biological display library includes a variety of display systems: phage surface display peptide library, yeast display peptide library, bacterial surface display peptide library, etc.; the cyclic peptide is presented on the cell surface by using the expression mechanism of the organism itself;

[0033] c. Construction of in vitro display library: The DNA nucleic acid fragment described in a is used to construct an in vitro display library, which includes an mRNA display polypeptide library, a ribosome display polypeptide library, etc.; an in vitro transcription and translation system is used to present the cyclic peptide on mRNA or ribosome;

[0034] d. Synthesis of chemical cyclic peptide library: using solid phase synthesis to synthesize chemical cyclic peptide library containing tandem motifs, etc.; controlling the sequence and structure of cyclic peptides through chemical synthesis;

[0035] The following is an explanation using two four-membered cyclic peptide skeletons as examples.

[0036] Constructing CPPCXCX m CX n CX o Phage four-membered cyclic peptide library in the form of CPPCXC, wherein m / n / o=5 / 5 / 5, 3 / 5 / 7 and 3 / 7 / 5; specifically, the polypeptide sequence displayed on the phage surface is:

[0037] CPPCXCXXXXXCXXXXXCXXXXXCPPCXC

[0038] CPPCXCXXXCXXXXXCXXXXXXXCPPCXC

[0039] CPPCXCXXXCXXXXXXXCXXXXXCPPCXC

[0040] Among them, X represents a random amino acid, which is encoded by NNK method, and random amino acid mutations are introduced at the specified position. The M13 phage display library ran-CPPCXC displaying the polypeptide is obtained, and the library diversity is 1.0×10 9 .

[0041] The peptide sequence displayed on the phage surface is:

[0042] CPXXCXCXXXXXCXXXXXXXXXXXCXCPXXC

[0043] Where X represents a random amino acid, which is encoded by NNK method to introduce random amino acid mutations at the specified position. The M13 phage display library ran-CPXXCXC displaying the polypeptide was obtained, and the library diversity was 5.5×10 8 The library has 7 fixed cysteines and the 8th cysteine ​​is randomly generated by NNK coding. It contains 22 tetracyclic peptide backbones. After translation modification, phages expressing tetracyclic DDMP can be obtained.

[0044] (3) Screening and identification

[0045] The constructed directional disulfide bond multicyclic peptide library is used to screen the active peptide sequences of the target protein;

[0046] The ran-CPPCXC three-skeleton phage cyclic peptide library was screened against the Keap1, EphA2 and HER3 targets, and the ran-CPXXCXC multi-skeleton phage cyclic peptide library was screened against the ICOS target. The avi tag biotinylated protein was fixed on the magnetic beads. After 3 and 4 rounds of screening, the enriched phage clones were randomly selected for sequencing.

[0047] Those skilled in the art will appreciate that the selection of target proteins is large and variable. They can be, for example, human or animal proteins, cytokines, cytokine receptors, enzyme cofactors of enzymes, or DNA binding proteins. Suitable target proteins include, but are not limited to, Keap1, HER3, EphA2, ICOS, etc. The above target proteins are not exhaustive.

[0048] According to the enriched peptide sequence obtained after sequencing, peptides are synthesized, including peptides targeting Keap1, peptides targeting EphA2, peptides targeting HER3, and peptides targeting ICOS; peptides are synthesized using solid-phase peptides and then subjected to oxidation reaction, and the four-membered cyclic peptides obtained after oxidation are named with the suffix "-Ox" (such as H1 oxidation product is H1-Ox). The affinity of each four-membered cyclic peptide with the target protein is tested using fluorescence polarization or surface plasmon resonance to test the effectiveness of the screening results.

[0049] Using E1, H2, H3, and I1 active sequences as peptide templates, partially randomized peptide sequences, and constructed phage secondary libraries sce-EphA2, sec-HER3, tri-HER3, and sec-ICOS, which were screened against Keap1, EphA2, and HER3 targets, respectively, to obtain DDMPs targeting EphA2, DDMPs targeting HER3, and DDMPs targeting ICOS with better affinity. The affinity of each tetracyclic peptide to the target protein was tested by surface plasmon resonance to test the validity of the screening results. The structure and disulfide bond pairing of H2'-Ox and I2'-Ox were determined by NMR, indicating that this method can effectively provide DDMP molecules with a completely new structure.

[0050] (4) Application

[0051] The peptides were synthesized by solid phase peptide and then oxidized to synthesize FITC-labeled tetracyclic peptides F-H4-Ox and F-I2-Ox. The F-I2-Ox dimer DI-F-I2-Ox was obtained by coupling reaction of DSS with F-I2-Ox. The transient HK293T cell line constructed by plasmids fused with target proteins (HER3 and ICOS, respectively) expressing mCherry was used to test the fluorescence co-localization of F-H4-Ox, F-I2-Ox, DI-F-I2-Ox and target proteins on the cell surface. The affinity of F-I2-Ox and DI-F-I2-Ox on ICOS-overexpressing cancer cells HuT-78 was determined by flow cytometry to illustrate that the affinity DDMP can be used as a detection probe molecule for cell surface target proteins.

[0052] The present invention develops a group of tandem motifs that can be used to guide the pairing of disulfide bonds in polypeptides, and provides methods for using them to design a polycyclic peptide skeleton for precise disulfide bond pairing and to construct a disulfide bond-rich cyclic peptide display library. The method further expands the diversity of the template skeleton of the polycyclic peptide library, and helps to screen functional cyclic peptide ligands and drugs targeting multiple proteins. All tandem motifs in the present invention can be used to design polycyclic peptide templates for efficient oxidative folding and can be applied to in vivo expression technology and in vitro expression technology, and can realize the construction of a variety of polycyclic peptide libraries for screening functional cyclic peptide ligands and drugs.

[0053] The present invention provides a four-membered cyclic peptide template that tolerates sequence modification, and realizes the precise pairing of four pairs of disulfide bonds in the four-membered cyclic peptide molecule. Combined with phage display technology, the four-membered cyclic peptide template is fused and expressed with the phage surface to construct a phage four-membered cyclic peptide library, which fully demonstrates the good compatibility between the tandem motif-guided multi-cyclic peptide method and the biological display technology.

[0054] Compared with the prior art, the present invention has the following outstanding advantages and technical effects:

[0055] a. The synthesis method of the cyclic peptide molecular skeleton constructed by the present invention is simple and can be achieved by conventional solid phase synthesis.

[0056] b. The present invention solves the problem of complex and uncontrollable products in the folding process of disulfide-bond-rich four-membered cyclic peptides. By introducing a tandem motif and utilizing the ability of the tandem motif to guide the pairing of multi-membered cyclic peptides, the four-membered cyclic peptide is oxidized to produce only a small number of isomers (one to two).

[0057] c. Compared with the previous technology of using non-natural amino acid insertion to regulate thiol pairing, the present invention involves natural amino acids and is suitable for the design of cyclic peptide libraries synthesized in vivo. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1Flowchart for the application of tandem motifs to design functionally directed disulfide-bonded polycyclic peptides.

[0059] Figure 2 The oxidative folding chromatograms of peptides 4-12 and mixed oxidized peptides 8 and 9 are shown.

[0060] Figure 3 Product yield bar graphs for peptides 4-12 and mixed oxidized peptides 8 and 9 (upper graph) and parallel (antiparallel) product definitions (lower graph).

[0061] Figure 4 This is the oxidative folding chromatogram of peptide 13-29.

[0062] Figure 5 Schematic diagram of the construction of a phage four-membered cyclic peptide library.

[0063] Figure 6 These are the oxidative folding chromatograms of active peptides K1, K2, E1-E5, H1-H7, I1-I3, F-K1, F-K2, F-H4 and F-I2.

[0064] Figure 7 The fluorescence polarization experiment of active peptides K1 / 2-Ox and F-K1 / 2-Ox. The left picture is the binding curve of F-K1 / 2-Ox and Keap1, the middle picture is the competition curve of K1 / 2-Ox and F-K1-Ox, and the right picture is the competition curve of K1 / 2-Ox and F-K2-Ox.

[0065] Figure 8 SPR sensorgrams of active DDMP molecules targeting EphA2, HER3, and ICOS.

[0066] Fig. 9 The NMR structures and disulfide bond pairing patterns of H2'-Ox (PDB ID is 8WW1) and I2'-Ox (PDB ID is 8WW0).

[0067] Fig.10 It is the specific binding between F-H4-Ox and HER3 on the cell surface.

[0068] Fig.11 It is the specific binding between F-I2-Ox, DI-F-I2-Ox and ICOS on the cell surface.

[0069] Fig.12 The synthesis of DI-F-I2-Ox (left) and the SPR method were used to determine the affinity of DI-F-I2-Ox for ICOS (right).

[0070] Fig.13Flow cytometry was used to characterize the affinity of F-I2-Ox and DI-F-I2-Ox for ICOS on the surface of cancer cells. DETAILED DESCRIPTION

[0071] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the following embodiments will further illustrate the present invention in conjunction with the accompanying drawings. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. On the contrary, the present invention covers any substitution, modification, equivalent method and scheme made on the essence and scope of the present invention as defined by the claims.

[0072] The present invention designs a group of tandem motifs, including nine types including CPPCXC, CXCPPC, CPPCPXXC, CPXXCPPC, CXCPXXC, CPXXCXC, CXCXC, CPPCPPC and CPXXCPXXC; wherein C represents cysteine, P represents proline, and X represents any amino acid. The tandem motif is derived from the tandem combination of disulfide bond-guided motifs (CPPC, CPXXC and CXC), and the motif can be regarded as a completely new whole by sharing the cysteine ​​in the middle of the motif. In particular, the direct tandem of disulfide bond motifs (such as CPPCCPPC) can be regarded as two independent CPPC motifs, which do not belong to the tandem motifs and are not in the technical solution of the present invention. The tandem motifs CPPCXC, CXCPPC, CPPCPXXC, CPXXCPPC, CPPCPPC and CXCXC all have a strong tendency to pair in parallel, and tolerate different numbers and positions of amino acid mutations in the motifs, which can drive the polypeptide disulfide bond exchange reaction to proceed in the direction of parallel pairing of the tandem motifs. The tandem motifs CPXXCXC, CXCPXXC and CPXXCPXXC have a certain tendency to pair in an antiparallel manner, which can drive the polypeptide to produce stable parallel pairing isomers and antiparallel pairing isomers, and the number of mutable amino acids in the motif is inconsistent. Therefore, the disulfide bond pairing mode desired by the present invention can be achieved by selecting different tandem motif combinations.

[0073] like Figure 1 As shown, the present invention provides a set of tandem motifs for designing a disulfide bond-guided multi-cyclic peptide library and a method for discovering multifunctional cyclic peptide ligands.

[0074] (1) Selecting tandem motifs to design a template for a directional disulfide bond polycyclic peptide backbone:

[0075] Template a: —aa m —A—aa n —

[0076] Among them, A represents a tandem motif (any of CPPCXC, CXCPPC, CPPCPXXC, CXCPXXC, CXCPXXC, CPXXCXC, CXCXC, CPPCPPC and CPXXCPXXC), aa represents any amino acid, and m and n represent the number of any amino acids.

[0077] Template b:—aa m —A—aa n —B—aa o —

[0078] Among them, A represents a tandem motif, B represents a tandem motif (any of CPPCXC, CXCPPC, CPPCPXXC, CXCPXXC, CXCPXXC, CPXXCXC, CXCXC, CPPCPPC and CPXXCPXXC), other disulfide bond-guided motifs or additional cysteine, the positions of A and B can be exchanged, aa represents any amino acid, and m, n, and o represent the number of amino acids.

[0079] Template c: -aa m —A—aa n —C—aa o —C—aa p —A—aa q —

[0080] Among them, A represents a tandem motif (any of CPPCXC, CXCPPC, CPPCPXXC, CXCPXXC, CXCPXXC, CPXXCXC, CXCXC, CPPCPPC and CPXXCPXXC), C represents an additional cysteine, the position between A and C can be exchanged, aa represents any amino acid, and m, n, o, p and q represent the number of amino acids.

[0081] According to the above template, polypeptides 4 to 29 were synthesized, a total of 25 model polypeptides (see Table 1); the above polypeptides are only for illustrating the design ideas of the present invention, and should not be regarded as the entire content of the present invention. In order to obtain the final desired disulfide bond pairing mode, the random amino acids in the tandem motif in the polypeptide can be arbitrarily replaced, the tandem motif can be arbitrarily replaced with other tandem motifs, the tandem motif (≥2) can also be partially replaced with other disulfide bond-guided motifs (such as CPPC, CPXXC or CXC) or additional cysteine, the number of random amino acids in the polypeptide template can also be reduced or increased as needed, and the position of the tandem motif and C can also be replaced. After the change, the concept of precise disulfide bond pairing is still applicable.

[0082] Table 1

[0083]

[0084] (2) Construction and application of four-membered cyclic peptide library

[0085] The peptide sequence displayed on the phage surface is:

[0086] CPPCXCXXXXXCXXXXXCXXXXXCPPCXC;

[0087] CPPCXCXXXCXXXXXCXXXXXXXCPPCXC;

[0088] CPPCXCXXXCXXXXXXXCXXXXXCPPCXC;

[0089] Where X represents a random amino acid, which is encoded by NNK method to introduce random amino acid mutations at the specified position.

[0090] Design the corresponding DNA sequence according to the above sequence:

[0091] 5'-TCGC ggcccagccggcc ATGGCATGCCCGCCGTGCnnkTGCnnknnknnknnnknnkTGCnnkn nknnknnknnkTGCnnknnknnknnnknkTGCCCGCCGTGCnnkTGCgcggccgcAAGGTGCGCCGG TG-3';

[0092] 5'-TCGC ggcccagccggcc ATGGCATGCCCGCCGTGCnnkTGCnnknnknnkTGCnnknnknnnk nknnkTGCnnknnknnknnnknnnknkTGCCCGCCGTGCnnkTGCgcggccgcAAGGTGCGCCGG TG-3';

[0093] 5'-TCGC ggcccagccggcc ATGGCATGCCCGCCGTGCnnkTGCnnknnknnkTGCnnknnknnnk nknnknnknnkTGCnnknnknnknnknnkTGCCCGCCGTGCnnkTGCgcggccgcAAGGTGCGCCGG TG-3';

[0094] The peptide sequence displayed on the phage surface is:

[0095] CPXXCXCXXXXXCXXXXXXXXXXXCXCPXXC;

[0096] Design the corresponding DNA sequence according to the above sequence:

[0097] 5'-TCGC ggcccagccggcc ATGGCATGCCCGnnknnkTGCnnkTGCnnknnknnknnknnkTGCnnknnknnknnknnknnnnnknnnknnknnkTGCnnkTGCCCGnnknnkTGCgcggccgcAAGGTGCGCC GGTG-3';

[0098] In the phagemid vector pCantab 5E, the library fragment was inserted using the double restriction sites of SfiI and NotI. The restriction endonuclease SfiI cleavage site in the DNA sequence of the fragment was indicated by lowercase and underline, the NotI cleavage site was indicated by lowercase and bold, and the polypeptide framework was indicated by bold and uppercase.

[0099] The library DNA fragments digested with SfiI / NotI and the phagemid vector pCantab 5E were ligated at a molar ratio of 1:10 using T4 DNA ligase to obtain the pCantab 5E recombinant plasmid. The three recombinant plasmids were mixed in equal molar ratios and electrotransformed into chemically competent Escherichia coli for ligation and transformation evaluation, and an M13 phage display library displaying the polypeptide was obtained, with a library diversity of 1.0×10 9 .

[0100] The constructed CPPCXC three-skeleton phage cyclic peptide library was screened against EphA2 and HER3 targets, and the CPXXCXC multi-skeleton phage cyclic peptide library was screened against ICOS target. The avi tag biotinylated protein was fixed on the magnetic beads. After 3 and 4 rounds of screening, the enriched phage clones were randomly selected for sequencing.

[0101] The following peptides were synthesized based on the enriched peptide sequences obtained after sequencing:

[0102] The synthesized peptides include: peptides E1, E2, E3, E4 and E5 targeting EphA2, peptides H1, H2, H3, H4, H5, H6, H7 targeting HER3, and peptides I1, I2 and I3 targeting ICOS (see Table 1).

[0103] The above 15 peptides were synthesized using solid phase peptides and then subjected to oxidation reaction. The four-membered cyclic peptides obtained after oxidation were named with the suffix "-Ox" (such as H1 oxidation product is H1-Ox). The affinity of each four-membered cyclic peptide with the target protein was tested using surface plasmon resonance to test the validity of the screening results.

[0104] (3) All the tandem motifs in the present invention can be used to design multi-cyclic peptide templates with efficient oxidative folding and can be applied to in vivo expression technology and in vitro expression technology, so that a variety of multi-cyclic peptide libraries can be constructed for screening functional cyclic peptide ligands and drugs.

[0105] The present invention provides a polypeptide backbone tm1-aa composed of different tandem motifs. n -tm2, used to generate ternary cyclic peptides, where tm1&tm2 represent tandem motifs, aa represents any amino acid, and n represents any number of amino acids; oxidative folding is performed under alkaline conditions to generate two ternary cyclic peptides with parallel tandem motifs or antiparallel tandem motifs; and almost no third isomer is produced. The ratio of parallel and antiparallel products can be controlled by adjusting different combinations of tandem motifs tm1 and tm2, and the ratio of parallel and antiparallel products can also be controlled by adjusting the number of random amino acids n between the tandem motifs. Generally, the more random amino acids n, the smaller the ring tension of the central peptide segment, and the smaller the impact on the ratio of parallel and antiparallel products. At this time, the product ratio is mainly affected by the oxidative pairing properties of the tandem motif combination. When tm1 and tm2 are the same, that is, when the same tandem motif is used to guide the oxidative folding of the ternary cyclic peptide, the pairing tendency of the tandem motif itself can affect the ratio of different disulfide bond pairing products, such as CPPCXC-aa n -CPPCXC skeleton oxidation mainly generates three-membered cyclic peptides with parallel pairing of CPPCXC motifs (yield> 80%); when different tandem motif combinations are selected (CPXXCXC-aa is recommended n -CXCPXXC,CPPCCXC-aa n -CXCPPC and other tandem motif combinations), mainly producing parallel and antiparallel ternary cyclic peptide isomers, but may produce a variety of oxidation products. Releasing the ring tension of the central peptide segment is conducive to the parallel pairing tendency of the tandem motif combination to guide the increase in the yield of parallel pairing ternary cyclic peptides. When n=15, the yield of parallel pairing ternary cyclic peptides generated by CPPCXC-15AA-CPPCXC is as high as 95%, completely inhibiting the generation of the other 14 isomers. Therefore, efficient oxidative folding of ternary cyclic peptides can be achieved by changing the tandem motif combination and the spacing distance of the tandem motifs.

[0106] A polypeptide skeleton with two CPPCXC motifs and two extra Cs (CPPCXC-CC-CPPCXC) was selected for oxidation reaction in alkaline aqueous solution, and the main product was a tetracyclic peptide with parallel pairing of CPPCXC motifs and pairing of extra cysteines. A tetracyclic peptide with a specific pairing pattern can be obtained by changing the position and distance between CPPCXC and the extra Cs.

[0107] The CPPCXC-CC-CPPCXC polypeptide skeleton was selected as a template, and the position and distance between CPPCXC and the extra C were changed to generate a variety of four-membered cyclic peptide skeletons. These skeletons were fused and expressed on the surface of phage to construct CPPCXCX m CX n CX o Phage tetracyclic peptide library in the form of CPPCXC (m / n / o = 5 / 5 / 5, 3 / 5 / 7 and 3 / 7 / 5) (library capacity: 1×10 9 ; X = any random amino acid). Select CPXXCXC-X5-CX 11 -CXCPXXC was expressed as a backbone fusion on the phage surface, and the eighth cysteine ​​was randomly generated by NNK method to construct a phage library containing 22 four-membered cyclic peptide patterns (library capacity: 5.5×10 8 ; X = any random amino acid). The peptide models Keap1, EphA2, HER3 and ICOS were selected as the screening model targets, respectively. After 3 to 4 rounds of bio-panning, the enriched phage clones were randomly selected for sequencing, and the enriched sequences were obtained. The enriched sequences of different targets were synthesized and oxidized, and all were efficiently oxidized and folded (yield: 74% to 100%) to obtain tetracyclic peptides ([I-VI, II-VII, III-VIII, IV-V]) that met the expected pairing. Through fluorescence polarization and SPR determination, these tetracyclic peptide molecules have micro-nanomolar affinity with the target (56nM-1.8μM). This proves that different tandem motif combinations can effectively regulate the folding mode of phage surface polypeptides, and for the first time, the construction of a tetracyclic peptide library containing four pairs of disulfide bonds on phage and the successful screening of multiple target proteins were realized.

[0108] HK293T cells transiently transfected with HER3-mChery and ICOS-mCherry plasmids were selected to explore the confocal imaging of fluorescently labeled tetracyclic peptides F-H4-Ox (targeting HER3), F-I2-Ox (targeting ICOS), and F-I2-Ox dimer (i.e., DI-F-I2-Ox) with HK293T cells overexpressing HER3 (or ICOS) on the surface, indicating that DDMP targeting HER3 (or ICOS) can specifically recognize the cell surface target protein. ICOS-overexpressing cancer cells HuT-78 were selected, and the binding force of F-I2-Ox and DI-F-I2-Ox on the cancer cell surface was determined by flow cytometry. The above experiments show that tandem motif-guided DDMP can be used as a research tool for chemical biology and a precursor of potential therapeutic drugs.

[0109] Example 1 Oxidation reaction of polypeptides 4 to 12

[0110] Taking the oxidation reaction of peptide 4 as an example, the specific oxidation method is: the solid powder of peptide 4 is dissolved in 100mM phosphate buffer (pH 7.4), and the peptide is quantified by UV-visible absorption spectroscopy. The following reaction solution is prepared using peptide 4 solution, 100mM phosphate buffer (pH 7.4) and DMSO: the final concentration of peptide 4 is 100μM, the final volume percentage of DMSO is 30%, and the total volume is 200μL. The above reaction solution is placed in a 37°C shaker for oxidation reaction for 10h. After the oxidation reaction is completed, an equal volume of 10% metaphosphoric acid solution is used to quench the reaction. The reaction product is separated, purified and identified by high performance liquid chromatography.

[0111] The above oxidation reaction method is also applicable to polypeptides 5 to 12, and the oxidation reaction steps are the same as those of polypeptide 4, except that when polypeptide 8 and polypeptide 9 are mixed and oxidized in equal proportions, the final concentration is 50 μM; the sequences of polypeptides 4 to 12 are shown in the sequence table SEQ ID NO.1 to 9.

[0112] The oxidation chromatograms of the above 9 peptides are shown in Figure 2 The molecular weight of the reaction products was determined by mass spectrometry, and the disulfide bond pairing patterns of each product were determined by protease cleavage, Acm orthogonal protection and NMR. The products and yield ratios are shown in Figure 3 .from Figure 3 It can be seen from the bar graph that after oxidation, polypeptides 4, 5, 6, 7, 10, and 12 mainly produce parallel paired oxidized dimers, with yields of 100%, 83%, 94%, 100%, 87%, and 94%, respectively, indicating that the CPPCXC, CXCPPC, CPPCPXXC, CPXXCPPC, CXCXC, and CPPCPPC motifs all have a tendency to produce parallel paired products after oxidation. The proportion of antiparallel products after oxidation of polypeptides 8, 9, and 11 is relatively high, at 5%, 23%, and 40%, respectively, indicating that the CXCPXXC, CPXXCXC, and CPXXCPXXC motifs all have a certain ability to induce antiparallel pairing. Mixed oxidation of polypeptides 8 and 9 can effectively obtain antiparallel paired heterodimers (yield of 21%), indicating that the mixed use of CXCPXXC and CPXXCXC motifs also has a certain ability to induce antiparallel pairing. Figure 3 The left side of the figure below shows that the cysteines near the N-terminus of the motif are paired in sequence to form disulfide bonds, which are parallel pairing products. Figure 3 In the figure below, on the right side, the cysteines in the motif near the N-terminus and the motif near the C-terminus are paired in sequence to form disulfide bonds as antiparallel pairing products.

[0113] Example 2 Oxidation reaction of polypeptides 13 to 29

[0114] Taking the oxidation reaction of peptide 13 as an example, the specific oxidation method is as follows: the solid powder of peptide 13 is dissolved in 100mM phosphate buffer (pH 7.4), and the peptide is quantified by UV-visible absorption spectroscopy. The following reaction solution is prepared using the above-mentioned peptide 13 solution, 100mM phosphate buffer (pH 7.4) and GSSG: the final concentration of peptide 13 in the peptide 13 solution is 50μM, the final concentration of GSSG is 500μM, and the total volume is 200μL. The above reaction solution is placed in a 37°C shaker for oxidation reaction for 6 to 8 hours. After the oxidation reaction is completed, an equal volume of 10% metaphosphoric acid solution is used to quench the reaction, and the reaction product is separated, purified and identified by high performance liquid chromatography. The above oxidation reaction method is also applicable to peptides 13 to 29. The oxidation reaction steps are the same as those of peptide 13. The difference is that some peptides (peptides 19, 20, 21, 22, 23 and 26) need to be additionally added with GSH to a final concentration of 50μM. The oxidation chromatograms of the above 16 peptides are shown in Figure 4 The sequences of polypeptides 13 to 29 are shown in the sequence table as SEQ ID NOs. 10 to 26. The molecular weight of the reaction products was identified by mass spectrometry, and the disulfide bond pairing of each product was identified by protease digestion and Acm orthogonal protection. The disulfide bond pairing of the oxidation products of polypeptides 13-29 and their yields are shown in Table 2.

[0115] Table 2

[0116]

[0117] As can be seen from Table 2, different combinations of tandem motifs can effectively guide the formation of parallel pairing [I-IV, II-V, III-VI] and antiparallel pairing [I-VI, II-V, III-IV] ternary cyclic peptides. Considering that there are 15 isomers of peptides containing six cysteines in theory, the oxidation yield of DDMP guided by tandem motifs has been greatly improved. After oxidation, peptide 13 mainly produced parallel pairing oxidation products (yield 83%), which was much higher than that of peptide 14 (31%) and peptide 15 (39%). This shows that although both the CPPCXC and CXCPPC motifs have a strong tendency to parallel pairing, the ability of the CPPCXC motif alone (corresponding to peptide 13) to guide the oxidation folding of the ternary cyclic peptide is stronger than that of the CPPCXC motif alone (corresponding to peptide 14) and the mixed use of the CPPCXC and CXCPPC motifs (corresponding to peptide 15). This is because the ring tension generated when the central peptide segment (i.e., nAA, referring to the number of amino acids between the motifs) is small hinders the formation of parallel pairing products. Releasing the tension of the central peptide ring (corresponding to peptide 16) can further improve the yield of parallel pairing products guided by the CPPCXC motif (95%). Similarly, the use of the CXCXC motif (corresponding to peptide 17) and the CPPCPPC motif (corresponding to peptide 18) alone also mainly produced parallel pairing and antiparallel pairing products, but their guiding abilities were weaker than that of using CPPCXC alone. The CPXXCXC-CXCPXXC motif combination (corresponding to peptide 22) can effectively guide the production of antiparallel pairing products (yield 58%), and the extension of the central peptide ring (corresponding to peptide 23) has little effect on the proportion of antiparallel pairing products (corresponding to peptide 24). The two tandem motif combinations corresponding to peptides 20 and 21 can produce [IV, II-VI, III-IV] ternary cyclic peptides, which helps to expand the diversity of cyclic peptides, but may also affect the oxidative folding efficiency of the same sequence. Through the oxidation reaction of peptides 24-26, it is shown that the tandem motif can effectively guide the production of ternary cyclic peptides with random sequences (-DISLFDE-) in the intermediate peptide. From the yields of 27-29 in Table 2, it can be seen that the use of the CPPCXC motif and additional cysteine ​​can effectively guide the polypeptide to form parallel paired [I-VI, II-VII, III-VIII, IV-V] tetracyclic peptides (yields are 92%, 83%, and 93%, respectively), indicating that the tandem motif can be used to guide the disulfide bond pairing of tetracyclic peptides.

[0118] The above polypeptides are only for illustrating the design ideas of the present technology, and should not be regarded as the entire content of the present invention. In order to obtain the disulfide bond pairing mode required by the present invention, random amino acids in the tandem motif in the polypeptide can be replaced at will, the tandem motif can be replaced at will with other tandem motifs, the tandem motif (≥2) can also be partially replaced with other disulfide bond-guided motifs (such as CPPC, CPXXC or CXC) or additional cysteine, the number of random amino acids in the polypeptide template can also be reduced or increased as needed, and the position of the tandem motif and C can also be replaced. After the change, the concept of precise disulfide bond pairing is still applicable. Therefore, all changes in polypeptide configuration and other modification methods made on the basis of the present invention should be regarded as within the scope of protection of the present invention.

[0119] Example 3 Construction of phage display four-membered cyclic peptide library

[0120] The present invention constructs two fully random phage four-membered cyclic peptide libraries and four customized phage four-membered cyclic peptide libraries. The peptide sequences and library capacities included in the libraries are shown in Table 3. The construction methods are shown in Figure 5 . First, order DNA primers encoding random amino acids in the NNK manner (for the DNA primers of the soft randomized library, use a mixture of 70% wild-type nucleotides and 10% other nucleotides for oligomerization), and recover the double-stranded DNA fragments by PCR amplification. The double-stranded DNA fragments contain SfiI and NotI double restriction sites and sequences encoding polypeptide frameworks. Use SfiI and NotI to digest the double-stranded DNA fragments and the phagemid vector pCantab 5E, respectively, and purify and recover. Use T4 DNA ligase to connect the restriction DNA fragments and the restriction phagemid vector pCantab 5E (molar ratio 1:10) to obtain the pCantab 5E recombinant plasmid. The recombinant plasmid (if the library is a multi-skeleton mixed library, mix the recombinant plasmids in equal proportions) is electrotransformed into chemically competent Escherichia coli for connection and transformation evaluation to obtain the M13 phage display library displaying the polypeptide. This experiment shows that the tandem motif can be directly used to construct a fully randomized polypeptide biological display library without borrowing the oxidative folding template of the natural disulfide-rich polypeptide.

[0121] Taking two fully random four-membered cyclic peptide libraries as examples, the design ideas of DNA double-cut fragments are explained.

[0122] Constructing CPPCXCX m CX n CX o Phage four-membered cyclic peptide library in the form of CPPCXC, wherein m / n / o=5 / 5 / 5, 3 / 5 / 7 and 3 / 7 / 5; specifically, the polypeptide sequence displayed on the phage surface is:

[0123] CPPCXCXXXXXCXXXXXCXXXXXCPPCXC;

[0124] CPPCXCXXXCXXXXXCXXXXXXXCPPCXC;

[0125] CPPCXCXXXCXXXXXXXCXXXXXCPPCXC;

[0126] Where X represents a random amino acid, which is encoded by NNK method to introduce random amino acid mutations at the specified position.

[0127] Design the corresponding DNA sequence according to the above sequence:

[0128] 5'-TCGC ggcccagccggcc ATGGCATGCCCGCCGTGCnnkTGCnnknnknnknnnknnkTGCnnkn nknnknnknnkTGCnnknnknnknnnknkTGCCCGCCGTGCnnkTGCgcggccgcAAGGTGCGCCGG TG-3';

[0129] 5'-TCGC ggcccagccggcc ATGGCATGCCCGCCGTGCnnkTGCnnknnknnkTGCnnknnknnnk nknnkTGCnnknnknnknnnknnnknkTGCCCGCCGTGCnnkTGCgcggccgcAAGGTGCGCCGG TG-3';

[0130] 5'-TCGC ggcccagccggcc ATGGCATGCCCGCCGTGCnnkTGCnnknnknnkTGCnnknnknnnk nknnknnknnkTGCnnknnknnknnknnkTGCCCGCCGTGCnnkTGCgcggccgcAAGGTGCGCCGG TG-3';

[0131] In the phagemid vector pCantab 5E, the library fragment was inserted using the double restriction sites of SfiI and NotI. The restriction endonuclease SfiI cleavage site in the DNA sequence of the fragment was indicated by lowercase and underline, the NotI cleavage site was indicated by lowercase and bold, and the polypeptide framework was indicated by bold and uppercase. Finally, the M13 phage display library ran-CPPCXC displaying the polypeptide was obtained, and the library diversity was 1.0×10 9 .

[0132] The peptide sequence displayed on the phage surface is:

[0133] CPXXCXCXXXXXCXXXXXXXXXXXCXCPXXC;

[0134] Design the corresponding DNA sequence according to the above sequence:

[0135] 5'-TCGC ggcccagccggcc ATGGCATGCCCGnnknnkTGCnnkTGCnnknnknnknnknnkTGCnnknnknnknnknnknnnnnknnnknnknnkTGCnnkTGCCCGnnknnkTGCgcggccgcAAGGTGCGCC GGTG-3';

[0136] In the phagemid vector pCantab 5E, the library fragment was inserted using the double restriction sites of SfiI and NotI. The restriction endonuclease SfiI cleavage site in the DNA sequence of the fragment was indicated by lowercase and underline, the NotI cleavage site was indicated by lowercase and bold, and the polypeptide framework was indicated by bold and uppercase. The library had 7 fixed cysteines, and the 8th cysteine ​​was randomly generated by NNK coding. It contained 22 four-membered cyclic peptide backbones. After translation modification, a phage expressing the four-membered cyclic DDMP was obtained. Finally, the M13 phage display library ran-CPXXCXC displaying the polypeptide was obtained, and the library diversity was 5.5×10 8 .

[0137] The name, framework and library capacity of the phage tetracyclic peptide library are shown in Table 3.

[0138] Table 3

[0139]

[0140] All nine tandem motifs in the present invention can be used to design highly efficient oxidative folding polycyclic peptide templates and can be applied to in vivo and in vitro expression techniques, so that a variety of polycyclic peptide libraries can be constructed for screening functional cyclic peptide ligands and drugs.

[0141] Example 4 Phage screening of different target proteins

[0142] 50 μL of streptavidin-modified magnetic beads (Thermo) or 100 μL of neutravidin-modified magnetic beads (Thermo) were placed in a protein low-adsorption centrifuge tube (Eppendorf), and the magnetic beads were washed twice with 1 mL of 1×PBS. After each wash, the supernatant and the magnetic beads were separated using a magnetic stand. Then, a certain amount of protein solution was added to the centrifuge tube (the control group added an equal amount of PBS), and the tube was placed at room temperature for 10 min and then washed three times with PBS. Then, 300 μL of PBS solution and 150 μL of 30 mg / mL BSA solution were added to the centrifuge tube. At the same time, the phage library (total amount greater than 2×10 12 pfu) with 1mL 30mg / mL BSA solution, and the two were placed in a 37℃ shaker for reaction for 2h. After the blocking was completed, the phage library was divided into two parts and added to the experimental group and the control group respectively, incubated at room temperature for 30min, the magnetic beads were collected using a magnetic stand, the clear solution was discarded, and the magnetic beads were washed several times with PBS solution and PBS solution containing 0.1% P20. After the washing was completed, the phage bound to the magnetic beads was eluted with 200μL 50mM Gly-HCl solution with pH=2.2, and the eluate was neutralized with 40μL 1M Tris-HCl solution with pH=8.0. Take out 10μL of the eluate to determine the polypeptide titer, and the remaining phages were put into the next round of panning. The Escherichia coli TG1 clone was selected and placed in 5 mL of 2YT medium for shaking culture. After the phage in the eluate was used to infect TG1, the supernatant was removed by centrifugation, and the precipitate was resuspended in 2YT medium. The suspension was then evenly spread on a solid medium with ampicillin resistance and placed in an incubator for overnight culture. After three to four bio-pannings, single clones were selected from the titer plate for sequencing. The enrichment results of phage library screening of different targets are shown in Table 4.

[0143] Table 4

[0144]

[0145] Example 5 Oxidation reaction of active DDMP

[0146] According to the enriched peptide sequence obtained after sequencing, peptides were synthesized, including peptides targeting Keap1, peptides targeting EphA2, peptides targeting HER3, and peptides targeting ICOS; after using solid-phase peptide synthesis for peptides, an oxidation reaction was performed, and the four-membered cyclic peptide obtained after oxidation was named with the suffix "-Ox" (such as H1 oxidation product is H1-Ox). Among them, the active peptides targeting Keap1 are K1, K2, F-K1 and F-K2, the active peptides targeting EphA2 are E1, E2, E3, E4 and E5, the peptides targeting HER3 are H1, H2, H3, H4, H5, H6, H7 and F-H4, and the peptides targeting ICOS are I1, I2, I3 and F-I2. The peptide sequence information is shown in Table 5.

[0147] Taking the oxidation reaction of polypeptide E1 as an example, the specific oxidation method is as follows: polypeptide E1 is made into solid powder, the polypeptide E1 solid powder is dissolved in 100mM phosphate buffer (pH 7.4) to prepare polypeptide E1 solution, and the polypeptide is quantified by UV-visible absorption spectroscopy. The following reaction solution is prepared using polypeptide E1 solution, 100mM phosphate buffer (pH 7.4) and GSSG (oxidized glutathione): the final concentration of polypeptide E1 is 50μM, the final concentration of GSSG is 500μM, and the total reaction solution volume is 200μL. The above reaction solution is placed in a 37℃ shaker for 6 to 12h. After the reaction is completed, an equal volume of 10% metaphosphoric acid solution is used to quench the reaction, and the reaction product E1-Ox is separated, purified, and identified by high performance liquid chromatography, and freeze-dried to prepare powder for subsequent experiments. The oxidation reaction steps of peptides K1-K2, E2-E5, H1-H7, F-K1, F-K2 and F-H4 are the same as those of peptide E1. Some peptides (peptides I1, I2, I3, F-I2) require additional GSH to a final concentration of 50 μM. The oxidation chromatograms of the above 21 peptides are shown in Figure 6 The sequences of polypeptides K1 to K2 are shown in the sequence listing as SEQ ID NOs. 27 to 28, the sequences of polypeptides E1 to E5 are shown in the sequence listing as SEQ ID NOs. 29 to 33; the sequences of polypeptides H1 to H7 are shown in the sequence listing as SEQ ID NOs. 34 to 40; the sequences of polypeptides I1 to I3 are shown in the sequence listing as SEQ ID NOs. 41 to 44, and the sequence of polypeptides F-I2 is shown in the sequence listing as SEQ ID NO. 45.

[0148] from Figure 6 It can be seen that the peptides targeting Keap1, EphA2, HER3 and ICOS all generated the corresponding four-membered cyclic peptide products with a high oxidation yield after oxidation. This fully demonstrates that the tandem motif can effectively guide the disulfide bond pairing of active peptides. At the same time, FITC-labeled F-K1, F-K2, F-H4 and F-I2 also maintained a high oxidation folding efficiency after oxidation, indicating that the fluorescent molecular labeling has little effect on the guiding ability of the tandem motif, making the tandem motif DDMP molecule have the potential to become a chemical biology research tool such as a molecular probe.

[0149] The sequence information of active peptides K1-K2, E1-E5, H1-H7, I1-I3 and fluorescent peptides is shown in Table 5.

[0150] Table 5

[0151]

[0152] Example 6 Determination of affinity between active DDMP and target protein (fluorescence polarization method)

[0153] The affinity of K1-Ox, K2-Ox and Keap1 was determined by fluorescence polarization competition binding experiment. This method uses fluorescence-modified F-K1-Ox, F-K2-Ox to bind to Keap1, and uses K1-Ox and K2-Ox to compete with F-K1-Ox and F-K2-Ox for binding to Keap1 to determine whether K1-Ox, K2-Ox and Keap1 bind to the same epitope.

[0154] The above polypeptide powder was used to prepare polypeptide solution with 10 mM PBS, and the reaction solution (wherein the fluorescent peptide concentration was constant at 20 nM) was prepared with the target protein solution. After being fully mixed, the reaction was carried out at room temperature in the dark for 10 min. After the reaction was completed, the reaction solution was immediately transferred to a black 96-well plate and the fluorescence anisotropy polarization value (λ ex =485nm,λ em =535nm). Then, the protein concentration-anisotropy value curve was drawn, and Origin and the following formula were used to fit the curve and calculate the dissociation constant K of the fluorescent peptide-protein. D value.

[0155]

[0156] Where: [PEP]0 is the fluorescent peptide concentration, a constant; [PRO]0 is the protein concentration, a variable; ΔA = A ∞ -A0; A0 is the anisotropy value of the fluorescent peptide in the free state; A ∞ is the anisotropy value when the fluorescent peptide and protein are in equilibrium; A is the anisotropy value when the protein concentration is [PRO]0; K D is the dissociation constant between the fluorescent peptide and protein.

[0157] The fluorescence polarization competition assay was performed using Origin and the following formula to fit the curve and calculate the peptide inhibition constant Ki.

[0158]

[0159]

[0160] Where: x is the logarithm of the concentration of the competing peptide, i.e., log[pep], a variable; A is the anisotropy value when the concentration of the competing peptide is [pep]; A max is the anisotropy of the fluorescent peptide in the absence of competitive peptide; A min EC is the anisotropy value when the competitive peptide and fluorescent peptide protein are in competition equilibrium; 50 Indicates the peptide concentration that can cause 50% of the maximum effect; [L]0 is the total concentration of fluorescent peptides; [P]0 is the total concentration of proteins. K Dis the dissociation constant between fluorescent peptide and protein; K i It represents the inhibition constant of the competing peptide on the fluorescent peptide.

[0161] from Figure 7 As shown in the left figure, the binding constants of F-K1-Ox and F-K2-Ox to Keap1 are 58nM and 176nM, respectively, indicating that the DDMP molecules screened by the tandem motif have nanomolar affinity with Keap1. Figure 7 In the middle and right figures of the experiment, it can be found that K1-Ox can compete with F-K1-Ox bound to Keap1 (inhibition constant Ki = 286nM), but cannot compete with F-K2-Ox bound to Keap1; similarly, K2-Ox can compete with F-K2-Ox bound to Keap1 (inhibition constant Ki = 113nM), but cannot compete with F-K1-Ox bound to Keap1. The above results collectively indicate that K1-Ox and K2-Ox have different binding epitopes to Keap1 and all have nanomolar affinity.

[0162] Example 7 Affinity determination of active DDMP and target protein (surface plasmon resonance method)

[0163] Surface Plasmon Resonance (SPR) technology was used to determine the DDMP targeting different target proteins (peptides E1-E5, H1-H7 and I1-I3 were replaced with the corresponding target proteins EphA2, HER3 and ICOS, respectively, and the test concentration gradient was shown in Figure 2. Figure 8 ), taking E1-Ox and EphA2 as an example, the specific test method is:

[0164] The assay was performed using the Cytiva Biacore T200 biomolecular interaction analysis system and the BioCAP chip, which is a chip capable of capturing biotinylated proteins. Before the experiment, the biotinylated target protein was immobilized on the surface of the BioCAP chip through biotin-streptavidin interaction, and the streptavidin sites of the reference channel and the experimental channel that were not bound to EphA2 were blocked with biotinylated BSA to reduce nonspecific binding. Subsequently, a 3.2 μM tetracycline solution was prepared and diluted in half to 0.375 μM to obtain a series of tetracycline solutions with gradient concentrations. Experimental conditions were set as follows: the experiment was carried out at a constant temperature of 25 ° C, the solution flow rate was 30 μL / min, the binding time was 60 s, and the dissociation time was 90 s. The tetracycline solutions of different concentrations were passed through the BioCAP chip in order from low to high according to the concentration gradient, and the time-response signal sensor graph was measured. After the initial experiment, the concentration range, binding practice and dissociation time were adjusted according to the experimental results, and the SPR sensor curve of the four-membered cyclic peptide and EphA2 was measured again. The sensor curve was fitted by Biacore T200 Evaluation Software, and the dissociation constant K was finally obtained. D Value. K D The K value is an important parameter to measure the binding affinity between molecules. D The smaller the value, the higher the binding affinity.

[0165] from Figure 8 It can be seen that the binding force of the active DDMP molecule E1-Ox targeting EphA2 to EphA2 is 4.9 μM, the binding force of E2-Ox to EphA2 is 2.6 μM, the binding force of E3-Ox to EphA2 is 2.8 μM, the binding force of E4-Ox to EphA2 is 4.9 μM, and the binding force of E5-Ox to EphA2 is 492 nM. The binding force of H1-Ox, an active DDMP molecule targeting HER3, to HER3 is 1.8μM, H2-Ox to HER3 is 1.1μM, H3-Ox to HER3 is 334nM, H4-Ox to HER3 is 56nM, H5-Ox to HER3 is 170nM, H6-Ox to HER3 is 283nM, and H7-Ox to HER3 is 990nM. The binding force of I1-Ox, an active DDMP molecule targeting ICOS, to ICOS is 1.8μM, I2-Ox to ICOS is 58nM, and I3-Ox1 to ICOS is 127nM. It shows that the active four-membered cyclic peptide molecules guided by tandem motifs targeting different target proteins have micro-nanomolar affinity with the target proteins and can be used to design multi-membered cyclic peptide ligands and therapeutic drugs with new structures and functions.

[0166] Example 8 The nuclear magnetic structures of H2'-Ox and I2'-Ox were determined by NMR method.

[0167] The sequence of polypeptide H2' is shown in the sequence list as SEQ ID NO.46, and the sequence of polypeptide I2' is shown in the sequence list as SEQ ID NO.47. Peptide H2'-Ox and I2'-Ox powders were dissolved in 50% deuterated acetonitrile and 50% water to a final concentration of 1 mM. NMR experiments were performed on a 850M BrukerAVANCE III NMR spectrometer equipped with an ultra-low temperature probe. Two-dimensional (2D) 1H-1H-TOCSY, 2D 1H-13C-HSQC and 2D 1H-15N-HSQC NMR spectra were recorded at 298K. 1H-1H distance constraints were obtained by 2D 1H-1H-NOESY experiments with mixing times of 50ms and 300ms. After the experiment, the chemical shifts of the polypeptide backbone and side chain atoms were identified from the spectra and analyzed using TopSpin 3.5 and NMRFAM-SPARKY. Finally, Xplor-NIH software was used for structure calculation and refinement.

[0168] The experimental results are shown in Fig. 9 , where the PDB ID of H2'-Ox is 8WW1 and the PDB ID of I2'-Ox is 8WW0. Fig. 9 It can be seen that the disulfide bond pairing mode of H2'-Ox is [I-VI, II-VII, III-VIII, IV-V], that is, the two CPPCXC motifs are paired in parallel, and the additional cysteines are paired. The peptide loop between the two parallel CPPCXC motifs shows a certain degree of distortion in space, forming a "roller coaster" type cysteine ​​pattern. A stable helical structure is formed between P15 and R23, which is compatible with the "roller coaster" type cysteine ​​pattern. The disulfide bond pairing mode of I2'-Ox is [I-VIII, II-VII, III-VI, IV-V], that is, the CPXXCXC and CXCPXXC motifs are paired in antiparallel, and the additional cysteines are paired. The active sequence forms a β-sheet structure, indicating that the β-sheet structure is also compatible with the cysteine ​​pattern guided by the tandem motif. The above results indicate that the tandem motif can construct a DDMP skeleton with a four-membered ring topology and is compatible with active secondary structures, and can be used to design polycyclic peptide ligands and therapeutic drugs with new structures and functions from scratch.

[0169] Example 9 Confocal imaging experiment of targeting polypeptide and target protein on the cell surface.

[0170] About 1.5×104 HEK293T cells were placed in a 35mm confocal culture dish, 1mL DMEM (containing 10% FBS) was added, and the cells were cultured in a 37°C cell culture incubator containing 5% CO2. After 24 hours, the target protein plasmid (HER3 or ICOS) fused with mCherry was transiently transferred into the HEK293T cells and continued to be cultured in the incubator. After another 24 hours, the cells were washed with PBS, and 1mL of DMEM (containing 10% FBS) containing fluorescent cyclic peptides (F-H4-Ox, F-I2-Ox and DI-F-I2-Ox) was added, and incubated at 37°C for 30 minutes. After the incubation, the cells were washed with DMEM and PBS, and the cell fluorescence images were taken with the Leica TCS SP8 confocal imaging system. The excitation light of FITC was 488 nm, and the fluorescence images were collected with absorption light of 506–571 nm; the excitation light of mCherry was 512 nm, and the fluorescence images were collected with absorption light of 605 nm and 670 nm.

[0171] from Fig.10 It can be seen that F-H4-Ox can bind to HER3 expressed on the cell surface; it also shows that when there are multiple protein receptors on the surface of living cells, the binding of H4-Ox to HER3 is specific. Fig.11 It can be seen that both F-I2-Ox and DI-F-I2-Ox can bind to ICOS expressed on the cell surface; the fluorescence confocal of 0.1μM F-I2-Ox and ICOS is no longer obvious, but 10nM and 1nM DI-F-I2-Ox can still bind to ICOS expressed on the cell surface.

[0172] Example 10

[0173] In this example, disuccinimidyl suberate (DSS) was first reacted with F-I2-Ox under weak alkaline conditions to obtain DI-F-I2-Ox, and the affinity of DI-F-I2-Ox to ICOS was determined by SPR. Fig.12 It can be seen that the affinity of DI-F-I2-Ox for ICOS is 0.20 nM, which has a subnanomolar affinity.

[0174] Flow cytometry was then used to verify that the fluorescent cyclic peptides F-I2-Ox and DI-F-I2-Ox specifically recognized ICOS on the surface of cancer cells. HuT-78 (low expression of ICOS) cells and Jurkat cells (no expression of ICOS) were used in the experiment. First, the suspended cells HuT-78 and Jurkat were centrifuged to remove the culture medium (the culture medium mentioned in this example was RPMI1640 culture medium containing 10% FBS), and the cells were resuspended in a small amount of culture medium and counted. About 1×106 HuT-78 cells were added to a centrifuge tube, and after centrifugation to remove the culture medium, 200 μL of culture medium containing a certain concentration of fluorescent cyclic peptides (F-I2-Ox or DI-F-I2-Ox) was added and incubated at room temperature for 30 minutes. After the incubation, the cells were washed and resuspended with PBS, and the cell fluorescence was analyzed using a CytoFLEX S flow cytometer. The treatment of Jurkat cells was similar to that of HuT-78 cells, and each group of experiments was repeated 3 times.

[0175] from Fig.13 It can be seen that the affinity of F-I2-Ox and DI-F-I2-Ox to ICOS on the surface of HuT-78 cells is 773nM and 180nM respectively, indicating that these two molecules can specifically recognize ICOS target protein on the surface of real cells. Examples 9 and 10 together illustrate that DDMP molecules with tandem motifs have the potential to become chemical biology research tools such as molecular probes.

[0176] Currently, there are only three motifs (CPPC, CXC and CPXXC) used to guide DDMPs, which can be used to develop bicyclic peptides and tricyclic peptide molecules. In order to expand the multi-cyclic peptide skeleton and structural diversity, it is necessary to continue to explore more disulfide bond-guided motifs for the subsequent development of multi-cyclic structures and functional DDMP molecules. A set of tandem motifs designed by the present invention has novel guided disulfide bond folding properties. Inserting two different tandem motifs into the polypeptide sequence can effectively regulate the disulfide bond pairing of the peptide chain and the folding of the polypeptide. By inserting different tandem motifs into the peptide chain, the construction of a DDMP skeleton with a four-membered ring topology can be achieved. This method does not require the use of an oxidative folding template of a natural disulfide-rich polypeptide, and can be used to directly construct a fully randomized polypeptide biological display library, and to design polycyclic peptide ligands and therapeutic drugs with new structures and new functions from scratch.

[0177] The above embodiments are only preferred embodiments of the present invention and cannot be considered to limit the scope of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the present invention.

Claims

1. A set of tandem motifs characterized by They are CPPCXC, CXCPPC, CPPCPXXC, CPXXCPPC, CXCPXXC, CPXXCXC, CXCXC, CPPCPPC and CPXXCPXXC respectively; wherein C represents cysteine, P represents proline and X represents any amino acid; The group of tandem motifs is composed of disulfide bond-guided motifs CPPC, CPXXC and CXC as building blocks, and a cysteine ​​is shared between the motifs, so that the various motifs form a whole in function and structure. The shared cysteine ​​forms a disulfide bond between motifs in the polypeptide chain to stabilize the folded state of the peptide chain.

2. A set of tandem motifs as claimed in claim 1, characterized in that The tandem motifs CPPCXC, CXCPPC, CPPCPXXC, CPXXCPPC, CPPCPPC and CXCXC have a tendency to pair in parallel, drive the polypeptide disulfide bond exchange reaction in the direction of parallel pairing of the tandem motifs, and tolerate different numbers and positions of amino acid mutations within the motifs.

3. A set of tandem motifs as claimed in claim 1, characterized in that The tandem motifs CPXXCXC, CXCPXXC and CPXXCPXXC have an antiparallel pairing tendency, which is used to drive the polypeptide to produce stable parallel pairing isomers and antiparallel pairing isomers, and the number of mutable amino acids in the motif is inconsistent.

4. A method for constructing a directed disulfide bond polycyclic peptide library and discovering polycyclic peptide ligands using a set of tandem motifs as claimed in claim 1, characterized in that The following steps are involved: (1) Select the following three templates with the following disulfide bond-rich cyclic peptide molecular skeletons: Pattern a: —aa m —A—aa n — Mock board b: —aa m —A—aa n —B—aa o — Template c: —aa m —A—aa n —C—aa o —C—aa p —A—aa q — Wherein, A represents any one of the group of tandem motifs CPPCXC, CXCPPC, CPPCPXXC, CXCPXXC, CXCPXXC, CPXXCXC, CXCXC, CPPCPPC, CPXXCPXXC, B represents a tandem motif, other disulfide bond-directed guiding motifs or additional cysteine, C represents additional cysteine, aa represents any amino acid, and m, n, o, p and q all represent the number of any amino acid; the other disulfide bond-directed guiding motifs are CPPC, CXC and CPXXC; in template b, the positions of A and B can be exchanged; in template c, the positions between A and C can be exchanged; (2) Construction of a directional disulfide bond polycyclic peptide library One of the three templates in step (1) is selected as the cyclopeptide backbone to construct a multi-component cyclopeptide library. The construction of the directional disulfide bond multi-component cyclopeptide library includes the following strategies: a. According to the tandem motif backbone in step (1), a DNA nucleic acid fragment containing the following sequence is synthesized, which forms a cyclic peptide structure containing a disulfide bond after translation: TGCCCGCCGTGCNNKTGC, translated as CPPCXC; TGCNNKTGCCCGCCGTGC, translated as CXCPPC; TGCCCGCCGTGCCCGNNKNNKTGC, translated as CPPCPXXC; TGCCCGNNKNNKTGCCCGCCGTGC, translated as CPXXCPPC; TGCNNKTGCCCGNNKNNKTGC, translated as CXCPXXC; TGCCCGNNKNNKTGCNNKTGC, translated as CPXXCXC; TGCNNKTGCNNKTGC, translated as CXCXC; TGCCCGCCGTGCCCGCCGTGC, translated as CPPCPPC; TGCCCGNNKNNKTGCCCGNNKNNKTGC, translated as CPXXCPXXC; Among them, using codon degeneracy, TGC is replaced by TGT, CCG is replaced by CCC, CCA, CCT, NNK refers to encoding random amino acid X by NNK degenerate codons, N in NNK codons represents A, T, C and G, K represents G and T; or random amino acid X is encoded by Trimer, IUBcode random amino acid encoding method; b. Construction of biological display library: The DNA nucleic acid fragments described in a are used for plasmid recombination to construct a biological display library; the biological display library includes a variety of display systems: phage surface display peptide library, yeast display peptide library, bacterial surface display peptide library; the cyclic peptide is fused and displayed on the organism by using the expression mechanism of the organism itself; c. Construction of in vitro display library: using the DNA nucleic acid fragments described in a to construct an in vitro display library, the in vitro display library includes an mRNA display polypeptide library and a ribosome display polypeptide library; using an in vitro transcription and translation system to present the cyclic peptide on mRNA or ribosome; d. Synthesis of chemical cyclic peptide library: Use solid phase synthesis to synthesize chemical cyclic peptide library containing tandem motifs; control the sequence and structure of cyclic peptides through chemical synthesis; (3) Screening and identification of polycyclic peptide ligands The constructed directional disulfide bond multi-cyclic peptide library is used to screen the active polypeptide sequence of the target protein, the target site of the target protein is screened, the enriched phage clones are selected for sequencing, and the multi-cyclic peptide ligands with high affinity and specificity to the target protein are screened; the screened multi-cyclic peptide ligands are structurally verified to confirm their disulfide bond connection mode and cyclic peptide structure.

5. A method for constructing a directed disulfide bond polycyclic peptide library and discovering polycyclic peptide ligands using a set of tandem motifs as claimed in claim 4, characterized in that In step (3), the target proteins include but are not limited to Keap1, HER3, EphA2, and ICOS.

6. Use of the multicyclic peptide ligand screened by the method of claim 4 as a probe in chemical biology research.

7. Use of the multicyclic peptide ligand screened by the method of claim 4 as a drug precursor in drug preparation.

8. The use according to claim 6 or 7, characterized in that Through chemical modification or biological modification methods, the N-terminus, C-terminus, cyclization mode, and amino acid sequence of the directional disulfide bond multi-cyclic peptide ligand are modified, or the tandem motif is completely or partially destroyed by non-natural amino acid replacement, ultimately serving as a research tool for chemical biology and a precursor molecule for the design of potential therapeutic drugs.

9. Use of a group of tandem motifs as claimed in claim 1 in screening functional cyclic peptide ligands and drugs targeting multiple proteins.